Bilirubin-A potential marker of drug exposure in atazanavir-based antiretroviral therapy

AAPS Journal

Volumn 13, Issue 4, 2011, Pages 598-605

  Rekić, Dinko ^a   Clewe, Oskar ^a   Röshammar, Daniel ^b   Flamholc, Leo ^c   Sönnerborg, Anders ^d   Ormaasen, Vidar ^e   Gisslén, Magnus ^f   Äbelö, Angela ^a   Ashton, Michael ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

atazanavir; bilirubin; HIV AIDS; pharmacodynamics; pharmacokinetics

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BILIRUBIN;

ARTICLE; BILIRUBIN BLOOD LEVEL; BILIRUBIN METABOLISM; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IC 50; NOMOGRAM; PATIENT COMPLIANCE; PHARMACODYNAMICS; SIMULATION;

BILIRUBIN; BIOLOGICAL MARKERS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; OLIGOPEPTIDES; PYRIDINES;

EID: 83555168318     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9299-0     Document Type: Article

References (35)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 2011.
2. F Josephson J Albert L Flamholc M Gisslén O Karlström L Moberg, et al. 2009 Treatment of HIV infection: Swedish recommendations 2009 Scand J Infect Dis 41 11-12 788 807 19922061 10.3109/00365540903214322 1:CAS:528:DC%2BD1MXhsVCrtLvP
3. D Zhang T Chando D Everett C Patten S Dehal W Humphreys 2005 In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation Drug Metabolism and Disposition 33 11 1729 16118329 10.1124/dmd.105.005447 1:CAS:528:DC%2BD2MXhtFOru7rI (Pubitemid 41539973)
4. D Smith S Jeganathan J Ray 2006 Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations HIV Clinical Trials 7 1 34 38 16632461 10.1310/0KX0-H9VH-99EE- 5D0L
5. R Cleijsen M Van de Ende F Kroon F Lunel P Koopmans L Gras, et al. 2007 Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice J Antimicrob Chemother 60 4 897 17704117 10.1093/jac/dkm298 1:CAS:528:DC%2BD2sXht1ygtbbM (Pubitemid 47434275)
6. S Rodríguez-Nóvoa L Martín-Carbonero P Barreiro G González-Pardo I Jiménez-Nácher J González-Lahoz, et al. 2007 Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia AIDS 21 1 41 17148966 10.1097/QAD. 0b013e328011d7c1 (Pubitemid 44912535)
7. G Monaghan M Ryan R Hume B Burchell R Seddon 1996 Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 347 9001 578 581 8596320 10.1016/S0140-6736(96)91273-8 1:CAS:528:DyaK28XitVGrtrc%3D (Pubitemid 26070740)
8. P Annaert Z Ye B Stieger P Augustijns 2010 Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1 Xenobiotica 40 3 163 176 20102298 10.3109/00498250903509375 1:CAS:528:DC%2BC3cXhslKqs7k%3D
9. Y Cui J König I Leier U Buchholz D Keppler 2001 Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6 J Biol Chem 276 13 9626 11134001 10.1074/jbc.M004968200 1:CAS:528: DC%2BD3MXis1Oltbw%3D
10. M Mediavilla L Pascolo J Rodriguez E Guibert J Ostrow C Tiribelli 1999 Uptake of [3H] bilirubin in freshly isolated rat hepatocytes: role of free bilirubin concentration FEBS Lett 463 1-2 143 145 10601655 10.1016/S0014- 5793(99)01606-3 1:CAS:528:DyaK1MXnvFems7Y%3D (Pubitemid 30001735)
11. R Hartkoorn W Kwan V Shallcross A Chaikan N Liptrott D Egan, et al. 2010 HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms Pharmacogenetics and Genomics 20 2 112 20051929 10.1097/FPC.0b013e328335b02d 1:CAS:528:DC%2BC3cXnvFyrsQ%3D%3D
12. S Campbell S de Morais J Xu 2004 Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia Chemico-Biological Interactions 150 2 179 187 15535988 10.1016/j.cbi.2004.08.008 1:CAS:528:DC%2BD2cXpsVKnsb4%3D (Pubitemid 39463281)
13. ES Perloff SX Duan PR Skolnik DJ Greenblatt LL von Moltke 2005 Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro Drug Metabolism and Disposition 33 6 764 15764714 10.1124/dmd.104.002931 1:CAS:528:DC%2BD2MXksleksrs%3D (Pubitemid 40686629)
14. AJ Busti RG Hall DM Margolis 2004 Atazanavir for the treatment of human immunodeficiency virus infection Pharmacotherapy 24 12 1732 1747 15585441 10.1592/phco.24.17.1732.52347 1:CAS:528:DC%2BD2MXhtlSgtg%3D%3D (Pubitemid 39578961)
15. S Rodriguez Novoa P Barreiro A Rendón A Barrios A Corral I Jimenez-Nacher 2006 Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C T polymorphism at the multidrug resistance gene 1 Clinical Infectious Diseases 42 2 291 295 16355344 10.1086/499056 (Pubitemid 43054206)
16. F Josephson M Andersson L Flamholc M Gisslén L Hagberg V Ormaasen, et al. 2010 The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients Eur J Clin Pharmacol 66 4 349 357 19967342 10.1007/s00228-009-0763-z 1:CAS:528:DC%2BC3cXjtlansb8%3D
17. K Petersen M Riddle L Jones K Furtek A Christensen S Tasker, et al. 2005 Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy AIDS 19 15 1700 16184044 10.1097/01.aids.0000186826.60983.85 1:CAS:528:DC%2BD2MXhtVeitr7O
18. O Karlström F Josephson A Sönnerborg 2007 Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy JAIDS Journal of Acquired Immune Deficiency Syndromes 44 4 417 10.1097/QAI.0b013e31802e2940 (Pubitemid 46555376)
19. Morello JE, Cuenca L, Vispo E. Use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy. AIDS research and human retroviruses. 2011;27(00):2-5. doi: 10.1089/aid.2011.0019.
20. A Edén LM Andersson Ö Andersson L Flamholc F Josephson S Nilsson, et al. 2010 Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients AIDS Research and Human Retroviruses 26 5 533 540 20455766 10.1089/aid.2009.0177
21. F Josephson J Albert L Flamholc M Gisslén O Karlström SR Lindgren, et al. 2007 Antiretroviral treatment of HIV infection: Swedish recommendations 2007 Scand J Infect Dis 39 6-7 486 507 17577810 10.1080/00365540701383154 1:CAS:528:DC%2BD2sXmsFOiurY%3D (Pubitemid 47017923)
22. M Gisslén J Ahlqvist-Rastad J Albert A Blaxhult AK Hamberg S Lindbäck, et al. 2006 Antiretroviral treatment of HIV infection: Swedish recommendations 2005 Scand J Infect Dis 38 2 86 103 16562361 10.1080/00365540500388834 (Pubitemid 43203233)
23. Beal SL SL, Boeckmann AJ (eds) Icon Development Solutions,, MD U, editors. NONMEM users guides. Ellicot City,1986-2006.
24. EN Jonsson MO Karlsson 1999 Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 1 51 64 10195646 10.1016/S0169-2607(98)00067-4 1:STN:280:DyaK1M3htVShsw%3D%3D (Pubitemid 29049052)
25. JJ Wilkins 2005 NONMEMory: a run management tool for NONMEM Comput Methods Programs Biomed 78 3 259 267 15899310 10.1016/j.cmpb.2005.02.003 (Pubitemid 40719673)
26. L Lindbom P Pihlgren EN Jonsson 2005 PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Comput Methods Programs Biomed 79 3 241 257 16023764 10.1016/j.cmpb.2005.04.005 (Pubitemid 41196689)
27. L Dickinson M Boffito D Back L Waters L Else G Davies, et al. 2009 Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers Journal of Antimicrobial Chemotherapy 63 6 1233 1243 19329800 10.1093/jac/dkp102 1:CAS:528:DC%2BD1MXmtFSgsbc%3D
28. B Anderson N Holford 2008 Mechanism-based concepts of size and maturity in pharmacokinetics Pharmacol Toxicol 48 1 303 10.1146/annurev.pharmtox.48. 113006.094708 1:CAS:528:DC%2BD1cXisFynu7g%3D (Pubitemid 351738156)
29. WJ Jusko HC Ko 1994 Physiologic indirect response models characterize diverse types of pharmacodynamic effects Clin Pharmacol Ther 56 4 406 419 7955802 10.1038/clpt.1994.155 1:CAS:528:DyaK2MXitFWqtb8%3D (Pubitemid 24339087)
30. PD Berk RB Howe JR Bloomer NI Berlin 1969 Studies of bilirubin kinetics in normal adults J Clin Investig 48 11 2176 5824077 10.1172/JCI106184 1:CAS:528:DyaE3cXlt1Kgtg%3D%3D
31. D Verotta L Sheiner 1995 A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data J Pharmacokinet Pharmacodyn 23 1 1 4 1:CAS:528:DyaK28XkslWltQ%3D%3D
32. W Krzyzanski WJ Jusko 2001 Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition J Pharmacokinet Pharmacodyn 28 1 57 78 11253614 10.1023/A:1011517718990 1:CAS:528:DC%2BD3MXit1ertr0%3D (Pubitemid 32500081)
33. S Pocock D Ashby A Shaper M Walker P Broughton 1989 Diurnal variations in serum biochemical and haematological measurements J Clin Pathol 42 2 172 2921359 10.1136/jcp.42.2.172 1:STN:280:DyaL1M7lsFyksw%3D%3D
34. T Manolio G Burke P Savage D Jacobs Jr S Sidney L Wagenknecht, et al. 1992 Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study Clin Chem 38 9 1853 1526025 1:STN:280:DyaK38vgsFChsA%3D%3D
35. G White Jr J Nelson D Pedersen K Ash 1981 Fasting and gender (and altitude?) influence reference intervals for serum bilirubin in healthy adults Clin Chem 27 6 1140 7237747 1:CAS:528:DyaL3MXkslyqsLc%3D